title: SDF-1 and CXCR4 in synovium are associated with disease activity and bone and joint destruction in patients with rheumatoid arthritis treated with golimumab.
abstract: OBJECTIVE
  The aim of this study was to determine whether the levels of stromal cell-derived factor (SDF)-1 and its receptor C-X-C chemokine receptor 4 (CXCR4) in synovium were correlated with clinical outcome and bone and joint destruction in rheumatoid arthritis (RA) patients being treated with golimumab.
  
  
  METHODS
  Synovial tissues were obtained from 15 golimumab-treated patients and were assessed for SDF-1 and CXCR4 using a new immunohistological scoring system (IH score). The IH score was used to assess correlations between synovial SDF-1 or CXCR4 and the disease activity score (DAS28 CRP), Rooney score, tumor necrosis factor alpha, interleukin-6 (IL-6), CD4, CD20, CD68 and the Assessment of RA by Scoring of Large-Joint Destruction and Healing in Radiographic Imaging (ARASHI) score. Receiver-operating characteristic (ROC) curves were used to predict ARASHI scores from the CXCR4 IH scores.
  
  
  RESULTS
  SDF-1 strongly correlated with the DAS28 CRP and serum IL-6. CXCR4 correlated with synovial CD4 and the ARASHI score. ROC analysis of CXCR4 and ARASHI scores >10 indicated a cutoff of 12 points on the IH score for predicting joint destruction during treatment.
  
  
  CONCLUSIONS
  Synovial SDF-1 correlated with disease activity, and its receptor CXCR4 was related to joint destruction in RA patients treated with golimumab.
authors.affiliation: a Department of Orthopaedic Surgery , Tokyo Women's Medical University, Medical Center East , Arakawa , Tokyo , Japan.
authors.forename: Katsuaki
authors.initials: K
authors.lastname: Kanbe
authors.affiliation: a Department of Orthopaedic Surgery , Tokyo Women's Medical University, Medical Center East , Arakawa , Tokyo , Japan.
authors.forename: Junji
authors.initials: J
authors.lastname: Chiba
authors.affiliation: a Department of Orthopaedic Surgery , Tokyo Women's Medical University, Medical Center East , Arakawa , Tokyo , Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Inoue
authors.affiliation: a Department of Orthopaedic Surgery , Tokyo Women's Medical University, Medical Center East , Arakawa , Tokyo , Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Taguchi
authors.affiliation: a Department of Orthopaedic Surgery , Tokyo Women's Medical University, Medical Center East , Arakawa , Tokyo , Japan.
authors.forename: Akiko
authors.initials: A
authors.lastname: Yabuki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D001842:Bone and Bones / Q000473:pathology; D054377:Chemokine CXCL12 / Q000378:metabolism*; D005260:Female; D006801:Humans; D015850:Interleukin-6; D008297:Male; D008875:Middle Aged; D019718:Receptors, CXCR4 / Q000378:metabolism*; D012720:Severity of Illness Index; D013583:Synovial Membrane / Q000378:metabolism* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000911:Antibodies, Monoclonal; C515255:CXCL12 protein, human; C527276:CXCR4 protein, human; D054377:Chemokine CXCL12; C508600:IL6 protein, human; D015850:Interleukin-6; D019718:Receptors, CXCR4; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab
keywords: CXC chemokine receptor type 4; Golimumab; Histology; Rheumatoid arthritis; Stromal cell-derived factor 1; Synovium